SCHEMBL5886891

SCHEMBL5886891

Cc1nc(N2CCN(c3ccccc3)CC2)nc2c1ccc(=O)n2-c1ccc(C(=O)NCc2ccccc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.44
MAPT P10636 2/20 0.44
CTNNB1 P35222 1/20 0.43
TCF7L2 Q9NQB0 1/20 0.43
KMT2A Q03164 2/20 0.43
RXFP1 Q9HBX9 2/20 0.42
MAPK8 P45983 2/20 0.42
MEN1 O00255 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ALDH1A1 P00352 3/20 0.41
LMNA P02545 2/20 0.41
HTR7 P34969 2/20 0.41
POLB P06746 2/20 0.41
AURKA O14965 1/20 0.40
HDAC1 Q13547 1/20 0.40
PDE2A O00408 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887425 0.96 HTR7 (0.45) TP53MAPTCTNNB1TCF7L2KMT2A
SCHEMBL5887641 0.96 MAPT (0.44) TP53MAPTCTNNB1TCF7L2KMT2A
SCHEMBL5886728 0.95 CTNNB1 (0.48) TP53MAPTCTNNB1TCF7L2LMNA
SCHEMBL5887548 0.94 KMT2A (0.46) TP53MAPTCTNNB1TCF7L2KMT2A
SCHEMBL5886779 0.94 MAPT (0.44) TP53MAPTCTNNB1TCF7L2RXFP1
SCHEMBL5886964 0.93 MAPK8 (0.45) MAPTCTNNB1TCF7L2KMT2ARXFP1
SCHEMBL5886882 0.93 MAPT (0.43) TP53MAPTKMT2ARXFP1MEN1
SCHEMBL5886707 0.93 ALDH1A1 (0.46) TP53MAPTCTNNB1TCF7L2RXFP1
SCHEMBL5886777 0.93 NAMPT (0.46) MAPTKMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL5886918 0.93 CTNNB1 (0.43) CTNNB1TCF7L2KMT2ARXFP1MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US disclosed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP TP53 43/4885MAPT 1614/4885CTNNB1 1452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.